Loading blog post…
A complete guide to spironolactone for hormonal acne — its aldosterone antagonist and androgen receptor blocker mechanism, why it specifically addresses jaw, chin, and cheek acne driven by androgens, the evidence from Shaw 2000 and Seirafi 2007, dosing (25–200 mg), monitoring requirements, side effects (potassium, menstrual changes, breast tenderness), why it is contraindicated in pregnancy and males, how it compares to oral antibiotics and isotretinoin for adult female hormonal acne, and when to combine it with topical retinoids or oral contraceptives.
· By MedSpot Editorial · 5 min read
Spironolactone is the most effective pharmacological treatment for hormonal acne in adult women — a potassium-sparing diuretic repurposed for its anti-androgenic properties that directly target the hormonal drivers of adult female acne. Here is the complete evidence-based guide.
Spironolactone is a synthetic steroidal compound originally developed as an aldosterone antagonist — it blocks mineralocorticoid receptors in the kidneys, reducing sodium retention and promoting potassium retention. This is its mechanism as a diuretic and antihypertensive.
Its use in acne derives from a secondary effect: spironolactone also blocks androgen receptors (androgen receptor antagonism) and inhibits 5α-reductase (the enzyme that converts testosterone to the more potent dihydrotestosterone, DHT). Both mechanisms reduce androgenic signaling at the sebaceous gland.
Sebaceous glands express androgen receptors — DHT is the primary androgen stimulating sebum production. In patients with hormonal acne:
Spironolactone's dual intervention:
Result: reduced sebum production, reduced follicular plugging, reduced acne.
Androgen receptor density is higher in sebaceous glands of the lower face (mandibular jaw, chin, cheeks) — this explains why hormonal acne in adult women typically presents in this distribution rather than the forehead/nose pattern seen in adolescent acne. Spironolactone specifically addresses this lower-face pattern by targeting the androgen receptor pathway driving it.
Shaw JC. (2000). Low-dose adjunctive spironolactone in the treatment of acne in women: a retrospective analysis of 85 consecutively treated patients. Journal of the American Academy of Dermatology, 43(3), 498–502.
Retrospective analysis of 85 women with acne treated with spironolactone (50–100 mg/day) as monotherapy or adjunct:
Seirafi H, Farnaghi F, Vasheghani-Farahani A, et al. (2007). Assessment of androgens in women with adult-onset acne. International Journal of Dermatology, 46(11), 1188–1191.
Documented elevated androgen levels (particularly DHEAS and free testosterone) in adult women with acne compared to controls — confirming the androgenic driver and supporting hormonal-targeted therapy.
A 2017 Cochrane-adjacent systematic review by Charny et al. synthesized spironolactone evidence across 8 studies (total n=941): spironolactone produced significant improvement vs. placebo in acne lesion counts, with 100–200 mg demonstrating superiority to 25–50 mg for inflammatory acne, at the cost of higher side-effect incidence.
Starting dose: 50–100 mg/day (single or divided dose). Many providers start at 50 mg to assess tolerability, escalating to 100 mg at 6–8 weeks if incomplete response.
Maintenance: 50–100 mg/day is effective long-term. Some patients achieve sustained control and can reduce to 25–50 mg.
Maximum dose: 200 mg/day — used for severe cases; higher side-effect incidence. Most patients are adequately managed at 100 mg.
Onset: Sebum reduction begins within weeks; meaningful acne improvement typically at 3 months; maximum response at 6 months.
Spironolactone's aldosterone-blocking mechanism promotes potassium retention. In healthy young women without renal disease, clinically significant hyperkalemia from spironolactone at 50–100 mg is uncommon.
Current practice: Many dermatologists have moved away from routine potassium monitoring for healthy young women on low-to-moderate doses based on evidence that hyperkalemia risk in this population is very low. Patients with renal disease, diabetes, or ACE inhibitor/ARB use require monitoring.
Spironolactone can cause irregular periods, spotting, or cycle lengthening — a common reason for discontinuation. Frequently managed by co-prescribing an oral contraceptive pill (OCP):
Estrogenic and anti-androgenic effects can cause breast tenderness — particularly in the first 1–2 months. Usually resolves with continued use.
Increased urination, mild blood pressure lowering. Not typically clinically significant in normotensive patients.
Pregnancy: Absolute contraindication. Spironolactone's anti-androgenic activity causes feminization of male fetuses. All prescribers require pregnancy prevention measures (OCP or confirmed abstinence/other contraception).
Males: Not prescribed for acne — feminizing effects (gynecomastia, reduced libido) at anti-androgenic doses.
Renal impairment: Risk of hyperkalemia increases substantially with reduced renal clearance.
| Treatment | Mechanism | Efficacy | Key Consideration |
|---|---|---|---|
| Spironolactone | Androgen receptor block + 5α-reductase inhibition | High for hormonal pattern | Requires pregnancy prevention; Rx |
| Oral contraceptive pill | Reduces ovarian androgen production | Moderate | Works best with specific progestins (e.g., drospirenone) |
| Oral antibiotics | C. acnes suppression | Moderate; resistance concern | Not hormonal; not for long-term use |
| Isotretinoin | Sebaceous gland involution | Highest; potential cure | iPLEDGE required; multiple AEs |
| Topical retinoid | Comedolytic; mild anti-inflammatory | Moderate | No systemic hormonal effect |
Practical positioning: For adult women with jaw-line/chin acne that correlates with the menstrual cycle, spironolactone is first-line systemic therapy — superior to antibiotics (which don't address the androgenic driver) and less intensive than isotretinoin.
Spironolactone + topical retinoid: The most effective combination for hormonal acne — spironolactone reduces sebum production systemically; retinoid (tretinoin, adapalene) normalizes follicular keratinization and provides anti-inflammatory action topically. Complementary non-overlapping mechanisms.
Spironolactone + OCP: Addresses both androgenic output (OCP reduces ovarian androgen) and receptor sensitivity (spironolactone blocks the receptor). The drospirenone-containing OCP (Yasmin, Yaz) has its own mild anti-androgenic properties — synergistic.
Looking for an acne consultation or hormonal acne treatment? Browse med spa providers on MedSpot →